August 2026 did not bring a newly approved treatment for acne-related hyperpigmentation. The meaningful changes are a July evidence review, a June serum trial, and a May switch that made a combination acne gel available without a prescription. Hyperpigmentation here means dark marks that remain after acne settles. The update matters because evidence increasingly supports preventing new marks by treating active acne while addressing existing pigmentation.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why the July review changes acne care
- What the new serum comparison actually found
- What the new over-the-counter acne gel changes
- A practical routine based on the update
- What evidence should readers watch next?
Why the July review changes acne care
acne-related pigmentation is not a minor cosmetic aftereffect. It disproportionately affects people with skin of colour, with reported prevalence ranging from 45.5% to 87.2%. Marks may remain for months or years after acne clears.
The July systematic review concluded that clinicians should manage pigmentation within routine acne care. That means prioritizing treatments that can control active breakouts while improving or preventing dark marks, rather than waiting until acne has resolved. However, the review does not identify one best regimen. Its 51 studies used varied methods, often had small samples, reported outcomes inconsistently, and provided limited data for specific skin phototypes, according to the Skin Health and Disease systematic review.
What the new serum comparison actually found
A randomized, double-blind trial in Mauritius followed 77 adults with skin phototypes III–VI for 84 days. Participants used SPF50+/UVA sunscreen with either a 2-MNG serum or a Thiamidol serum. Both groups had significant improvement in post-acne pigmentation. The primary result showed that 2-MNG was non-inferior to Thiamidol.
In plain terms, it performed no worse within the trial's predefined margin; the study did not prove it was superior. The full comparison appeared in the Journal of Cosmetic Dermatology. The result is encouraging but not practice-changing by itself. La Roche-Posay supported the study, and several authors worked for L'Oréal. Independent, multicentre trials are needed before readers can treat either serum as the clear winner.
What the new over-the-counter acne gel changes
On May 22, 2026, the FDA approved the prescription-to-nonprescription switch of Differin Epiduo Acne Gel. It combines adapalene 0.1% with benzoyl peroxide 2.5% and is intended for acne in adults and children aged 12 or older, according to the FDA switch notice. The gel does not directly treat hyperpigmentation.
Its relevance is preventive: controlling active acne may reduce the new breakouts that leave additional marks. The FDA label says irritation is especially likely during the first four weeks and when people use multiple topical acne medicines. Because irritation can worsen dark marks, applying more often or stacking products aggressively may undermine the goal.
A practical routine based on the update
The evidence supports a steady routine that addresses breakouts, pigmentation, sun exposure, and irritation together: Patience remains part of treatment. The American Academy of Dermatology says shallow dark marks commonly need six to 12 months to fade after the trigger stops, while deeper pigment can last for years, as explained in its guidance on fading dark spots.
- Treat active acne and existing dark marks at the same time.
- Use broad-spectrum SPF 30 or higher every day.
- Consider a tinted sunscreen containing iron oxide when suitable, because visible light can contribute to dark spots.
- If using the new adapalene–benzoyl peroxide gel, follow the once-daily label directions.
- Use moisturizer and avoid adding several topical acne medicines at once.
What evidence should readers watch next?
The next useful development would be stronger confirmation, not another ingredient announcement. Important evidence would include independent multicentre trials, larger samples, consistent pigment measurements, and results separated by skin phototype.
Researchers also need to evaluate acne control and pigment improvement together. Until those data arrive, non-inferiority in one 77-person trial does not establish a best serum or regimen.